Last Updated: May 26, 2026

Claims for Patent: 10,544,228

✉ Email this page to a colleague

Summary for Patent: 10,544,228

Title:	Nucleic acids encoding antibody polypeptides that antagonize CD40
Abstract:	Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
Inventor(s):	Anish SURI, Steven Sheriff, Suzanne Suchard, Aaron YAMNIUK, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip DREW
Assignee:	Domantis Ltd , Bristol Myers Squibb Co
Application Number:	US15/259,828

Details for Patent 10,544,228

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Elusys Therapeutics, Inc.	ANTHIM	obiltoxaximab	Injection	125509	March 18, 2016	⤷ Start Trial	2036-09-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,544,228

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012145673	⤷ Start Trial
United States of America	9475879	⤷ Start Trial
United States of America	2020199244	⤷ Start Trial
United States of America	2017015754	⤷ Start Trial
United States of America	2014099317	⤷ Start Trial
United States of America	11136406	⤷ Start Trial
Taiwan	I598363	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.